Fidelis Capital Partners LLC Buys 964 Shares of Stryker Co. (NYSE:SYK)

Fidelis Capital Partners LLC grew its stake in shares of Stryker Co. (NYSE:SYK) by 39.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 3,402 shares of the medical technology company’s stock after acquiring an additional 964 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Stryker were worth $1,331,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Stryker during the 4th quarter valued at $25,000. Dunhill Financial LLC raised its holdings in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares in the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Stryker during the 4th quarter worth $30,000. BankPlus Trust Department acquired a new position in shares of Stryker during the 4th quarter worth $33,000. Finally, Darwin Wealth Management LLC acquired a new position in shares of Stryker during the 3rd quarter worth $36,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Up 2.2 %

Shares of NYSE:SYK opened at $394.53 on Tuesday. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a market cap of $150.54 billion, a PE ratio of 50.84, a P/E/G ratio of 2.93 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The stock’s 50-day moving average is $381.06 and its 200 day moving average is $371.92.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the business posted $3.46 EPS. Sell-side analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.85%. Stryker’s dividend payout ratio is currently 43.30%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SYK. Royal Bank of Canada upped their target price on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. The Goldman Sachs Group increased their price target on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a report on Thursday, January 30th. JPMorgan Chase & Co. increased their price objective on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Wells Fargo & Company raised their target price on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Finally, Truist Financial raised their price target on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a report on Thursday, January 30th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus price target of $422.15.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.